Loading stock data…
AtaiBeckley Inc (ATAI)
$7.28-0.11 (-1.49%)
After Hours$7.31+0.03 (+0.41%)· Last close Sep 8
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AtaiBeckley Inc. in the Healthcare sector is trading at $7.28 with a market capitalization of $1.4B. Wall Street consensus targets $8.10 (7 analysts), implying a +11.3% move over the next 12 months. The stock is currently near its 52-week high of $7.45, remaining 55.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $954,000↓ | $1.07M↑ | $749,000↑ | $719,000↓ | $1.55M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$30.16M↑ | -$39.35M↓ | -$28.41M↓ | -$25.25M↓ | -$20.34M |
| Net Income | -$29.78M↑ | -$544.81M↓ | -$61.07M↓ | -$27.73M↓ | -$26.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-333.90%
Volume
Today's trading volume
119.74M
Recent News
Eli Lilly Strikes $2.88 Billion Deal to Buy Merida Biosciences
Eli Lilly (LLY) has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, as it see
Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio.
3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now
Psychedelics stocks are becoming more popular as more research goes into them. Here are 3 stock ideas for your watchlist.
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
The mean of analysts' price targets for AtaiBeckley Inc (ATAI) points to a 31.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Eli Lilly Stock: The One Question in Otherwise Perfect Earnings and What It Means for Shares
Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications, though one glaring question hung over the print. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.